SGS's Life Science Services, 820 W Diamond Ave, Gaithersburg, MD 20878, US

Yiseng US Biopharma is a global biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of vaccines and therapeutic biologics for infectious diseases and cancer. With a dedicated team of over 800 employees and a presence in multiple countries, including China, Singapore, the United States, the United Arab Emirates, and the Philippines, Yiseng US Biopharma utilizes its proprietary PIKA immunomodulating technology platform to develop a diverse range of biotherapeutics targeting diseases such as COVID-19, hepatitis B, rabies, flu, and various forms of cancer. Through their PIKA technology, which activates multiple pathways of immune signaling, including TLR3, RIG-I, and MDA5, Yiseng US Biopharma is at the forefront of developing innovative antiviral vaccines, antiviral therapeutics, and anticancer therapeutics. Their pipeline includes PIKA-based vaccines for infectious diseases and PIKA-based immuno-oncology candidates that have demonstrated potent antitumor effects in preclinical studies. With a strong focus on advancing novel immunotherapeutics, Yiseng US Biopharma is committed to making significant contributions to the field of biopharmaceuticals.Generated from the website

Maxar Intelligence

Lifework Strategies

Rios, Norval A MD

Icon Clinical Research